Abstract
Purpose
Ectopic ACTH syndrome (EAS) is rare. We established a national cohort to increase awareness and address unmet needs.
Methods
The Finnish national EAS cohort includes 60 patients diagnosed in 1997–2016. We assessed clinical features, diagnostic work-ups, treatments, incidence, and outcomes of subgroups occult tumor (OT), well-differentiated neuroendocrine tumor G1/G2 (NETG1/G2) and NET G3/neuroendocrine carcinoma (NETG3/NEC).
Results
The distribution of OT, NETG1/G2, and NETG3/NEC was 10 (17%), 20 (33%), and 30 (50%), respectively; and median follow-up 22 months (0–249). Annual incidence (0.20–0.93 per million inhabitants) and tumor subgroups (OT vs. NEC) varied across the country. The longest diagnostic delay from EAS onset to radiological tumor identification was 48 months. In NET/NEC, 6/50 (12%) were diagnosed 1–24 years before EAS onset. Osteoporotic fractures (32%) and severe infections (55%) were common. The CRH stimulation test accurately diagnosed EAS in 25/31 (81%). Metyrapone (≤6 g daily, prescribed in 88%) was well tolerated. In NETG1/G2, 13/20 (65%) underwent curative resection of the primary tumor; four experienced recurrence within 2–12 years. In OT, 70% underwent bilateral adrenalectomy. Five-year overall survival in OT, NETG1/G2, and NETG3/NEC was 90%, 55%, and 0%, respectively (P < 0.001). Morning cortisol, hypokalemia, infections, metastatic disease, and acute onset were negative, whereas resection of the primary tumor and bilateral adrenalectomy were positive predictors of survival.
Conclusions
NET/NEC may precede EAS onset by several years. In NETG1/G2, recurrences may occur > 10 years after successful primary surgery. Tumor subgroup (OT, NETG1/G2, NEC) was an independent predictor of survival.
Similar content being viewed by others
Availability of data and material
(Data transparency) yes.
Code availability
(Software application or custom code) not applicable (word document and figure files).
References
I. Ilias, D.J. Torpy, K. Pacak, N. Mullen, R.A. Wesley, L.K. Nieman, Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J. Clin. Endocrinol. Metab. 90, 4955–4962 (2005)
J. Young, M. Haissaguerre, O. Viera-Pinto, O. Chabre, E. Baudin, A. Tabarin, MANAGEMENT OF ENDOCRINE DISEASE: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur. J. Endocrinol. 182, R29–R58 (2020)
K.I. Alexandraki, A.B. Grossman, The ectopic ACTH syndrome. Rev. Endocr. Metab. Disord. 11, 117–126 (2010)
A. Osswald, T. Deutschbein, C.M. Berr, E. Plomer, A. Mickisch, K. Ritzel, J. Schopohl, F. Beuschlein, M. Fassnacht, S. Hahner, M. Reincke, Surviving ectopic Cushing’s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing’s disease during long-term follow-up. Eur. J. Endocrinol. 179, 109–116 (2018)
M.V. Davi’, E. Cosaro, S. Piacentini, G. Reimondo, N. Albiger, G. Arnaldi, A. Faggiano, G. Mantovani, N. Fazio, A. Piovesan, E. Arvat, F. Grimaldi, L. Canu, M. Mannelli, A.G. Ambrogio, F. Pecori Giraldi, C. Martini, A. Lania, M. Albertelli, D. Ferone, M.C. Zatelli, D. Campana, A. Colao, C. Scaroni, M. Terzolo, L. De Marinis, S. Cingarlini, R. Micciolo, G. Francia, Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: a multicenter study. Eur. J. Endocrinol. 176, 453–461 (2017)
A.R. Hayes, A.B. Grossman, The ectopic adrenocorticotropic hormone syndrome: rarely easy, always challenging. Endocrinol. Metab. Clin. North Am. 47, 409–425 (2018)
G. Rindi, D.S. Klimstra, B. Abedi-Ardekani, S.L. Asa, F.T. Bosman, E. Brambilla, K.J. Busam, R.R. de Krijger, M. Dietel, A.K. El-Naggar, L. Fernandez-Cuesta, G. Klöppel, W.G. McCluggage, H. Moch, H. Ohgaki, E.A. Rakha, N.S. Reed, B.A. Rous, H. Sasano, A. Scarpa, J.Y. Scoazec, W.D. Travis, G. Tallini, J. Trouillas, J.H. van Krieken, I.A. Cree, A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 31, 1770–1786 (2018)
C. Schalin-Jäntti, A. Ahonen, M. Seppänen, 18F-DOPA PET/CT but not 68Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome. Clin. Nucl. Med. 37, 904–905 (2012)
C. Schalin-Jäntti, S.L. Asa, J. Arola, T. Sane, Recurrent acute-onset Cushing’s syndrome 6 years after removal of a thymic neuroendocrine carcinoma: from ectopic ACTH to CRH. Endocr. Pathol. 24, 25–29 (2013)
J.E. Paleń-Tytko, E.M. Przybylik-Mazurek, E.J. Rzepka, D.M. Pach, A.S. Sowa-Staszczak, A. Gilis-Januszewska, A.B. Hubalewska-Dydejczyk, Ectopic ACTH syndrome of different origin-Diagnostic approach and clinical outcome. Experience of one Clinical Centre. PLoS One 15, e0242679 (2020)
I. Lase, I. Strele, M. Grönberg, G. Kozlovacki, S. Welin, E.T. Janson, Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing’s syndrome. Hormones 19, 351–360 (2020)
: Facts on Finland and Finnish Health Care system. In: Martikainen, J., Pajunen, R., Saastamoinen, L., Kalliokoski, A., Voipio, T. (eds.) Suomen lääketilasto Finnish Statistics on Medicines 2010, pp. 37-39. Finnish Medicines Agency Fimea and the Social Insurance Institution (Kela), Helsinki (2011)
C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jørgensen, Epidemiology of Cushing’s syndrome. Neuroendocrinology 92(Suppl 1), S1–S5 (2010)
A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)
G. Rubinstein, A. Osswald, E. Hoster, M. Losa, A. Elenkova, S. Zacharieva, M.C. Machado, F.A. Hanzu, S. Zopp, K. Ritzel, A. Riester, L.T. Braun, I. Kreitschmann-Andermahr, H.L. Storr, P. Bansal, M.J. Barahona, E. Cosaro, S.C. Dogansen, P.C. Johnston, R. Santos de Oliveira, C. Raftopoulos, C. Scaroni, E. Valassi, S.J.A. van der Werff, J. Schopohl, F. Beuschlein, M: Reincke, Time to diagnosis in Cushing’s syndrome: a meta-analysis based on 5367 patients. J. Clin. Endocrinol. Metab. 105, dgz136 (2020). https://doi.org/10.1210/clinem/dgz136
J.P. Aniszewski, W.F. Young Jr, G.B. Thompson, C.S. Grant, J.A. van Heerden, Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J. Surg. 25, 934–940 (2001)
F. Beuschlein, G.D. Hammer, Ectopic pro-opiomelanocortin syndrome. Endocrinol. Metab. Clin. North Am. 31, 191–234 (2002)
G. Klöppel, S. La Rosa, Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 472, 341–349 (2018)
A.M. Isidori, A. Lenzi, Ectopic ACTH syndrome. Arq. Bras. Endocrinol. Metabol. 51, 1217–1225 (2007)
A.M. Isidori, E. Sbardella, M.C. Zatelli, M. Boschetti, G. Vitale, A. Colao, R. Pivonello; ABC Study Group, Conventional and nuclear medicine imaging in ectopic Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 100, 3231–3244 (2015)
A.M. Isidori, G.A. Kaltsas, C. Pozza, V. Frajese, J. Newell-Price, R.H. Reznek, P.J. Jenkins, J.P. Monson, A.B. Grossman, G.M. Besser, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J. Clin. Endocrinol. Metab. 91, 371–377 (2006)
S. Sathyakumar, T.V. Paul, H.S. Asha, B.R. Gnanamuthu, M.J. Paul, D.T. Abraham, S. Rajaratnam, N. Thomas, Ectopic Cushing syndrome: a 10-year experience from a tertiary care center in Southern India. Endocr. Pract. 23, 907–914 (2017)
Acknowledgements
This study was supported by grants from the Helsinki University Hospital Research Funds (TYH2018223, TYH2019254) and Finska Läkaresällskapet (not numbered) (to C.S.-J.).
Author information
Authors and Affiliations
Contributions
All authors contributed sufficiently (data collection, approving final manuscript as the minimum) to be listed as authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Ethical approval
This study was conducted in accordance with the Declaration of Helsinki. Authorization to perform this study without individual consent was granted by the Ethical Committee of the Helsinki University Central Hospital (HUS 2024/2016) and the Review Boards of the individual hospitals.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Toivanen, S., Leijon, H., Arola, A. et al. Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort. Endocrine 74, 387–395 (2021). https://doi.org/10.1007/s12020-021-02768-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02768-0